Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Bladé, Joan  [Clear All Filters]
2023
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, P Ho J, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2023.
2022
Sanfeliciano TContreras, Roca CAgullo, Martínez-López J, Oriol A, Blanchard M-J, Ríos-Tamayo R, Sánchez JMartín, M Iñigo B, Sureda A, Garcia M-TTHernande, et al. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Adv. 2022.
2021
Botta C, Maia CDa Silva, Garcés J-J, Termini R, Perez C, Manrique I, Burgos L, Zabaleta A, Alignani D, Sarvide S, et al. FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology. Blood Adv. 2021.
Molina-Andújar A, Tovar N, Cuadrado E, de Anta NCastrejón, Revuelta I, Cucchiari D, Cofan F, Esforzado N, M Cibeira T, Rosiñol L, et al. Kidney Transplantation in Monoclonal Immunoglobulin Deposition Disease: A Report of 6 Cases. Am J Kidney Dis. 2021.
Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e105-e118.
2020
Rodríguez-Lobato L-G, Martínez-Roca A, Castaño-Díez S, Palomino-Mosquera A, Gutiérrez-García G, Pedraza A, Suárez-Lledó M, Rovira M, Martínez C, de Larrea CFernández, et al. The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. PLoS One. 2020;15(11):e0241778.
2019
Gutiérrez-García G, Cibeira MTeresa, Rovira M, de Larrea CFernández, Tovar N, Rodríguez-Lobato LGerardo, Rosiñol L, Marín P, Solano-Vega J, Suárez-Lledó M, et al. Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis. Bone Marrow Transplant. 2019.
2016
Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T, Dmoszynska A, Horvath N, Spicka I, et al. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma. Cancer. 2016.
2015
Mateos M-V, Oriol A, Rosiñol L, de Arriba F, Puig N, Martín J, Martínez-López J, Echeveste M-A, Sarrá J, Ocio E, et al. Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial. Haematologica. 2015.
Cibeira MT, Oriol A, Lahuerta JJ, Mateos M-V, de la Rubia J, Hernández MT, Granell M, de Larrea CFernández, San Miguel JF, Bladé J. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. Br J Haematol. 2015.
2013
Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJosé, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, et al. Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. J Clin Oncol. 2013.
Tovar N, de Larrea CFernández, Pedrosa F, Aróstegui JI, Cibeira MTeresa, Rosiñol L, Elena M, Filella X, Yagüe J, Bladé J. Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma. Ann Hematol. 2013.
Tovar N, de Larrea CFernández, Aróstegui JI, Cibeira MTeresa, Rosiñol L, Rovira M, Elena M, Filella X, Yagüe J, Bladé J. Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem-cell transplantation: long-term results from a single institution. Haematologica. 2013.